Table of Contents Show
The intersection of neuroscience, artificial intelligence, and consumer wellness technology has produced a compelling new entrant. Sychedelic, a neurotech startup headquartered across Gurugram and New York, has closed a $3.5 million seed funding round, drawing participation from institutional backers TurboStart, Ideabaaz, and Praveek Ventures, as well as a network of angel investors spanning India, the UAE, and the broader NRI community. The raise marks a significant vote of confidence in the company’s vision to bring clinically informed brain stimulation technology into everyday consumer use.
A Device Built for the Modern Mind
At the heart of Sychedelic’s proposition is a wearable designed in the form factor of conventional headphones — an intentional choice that prioritises accessibility and daily usability. Unlike traditional neurostimulation tools confined to clinical environments, the device is engineered for real world conditions. It combines transcranial direct current stimulation (tDCS), binaural beats, and heart rate variability (HRV) biofeedback within a single, adaptive system. An embedded AI layer continuously monitors and responds to the user’s mental state in real time, dynamically adjusting stimulation parameters accordingly. The result, according to the founders, is a truly closed loop neuroadaptive experience targeting stress reduction, improved focus, sleep support, and broader mental wellness.
From Concept to Validated Product
Sychedelic has not simply arrived at the funding stage on the strength of an idea alone. Over the past six months, more than 100 early adopters have actively used the device, providing the founding team Ria Rustagi and Bhavya with granular, real world feedback to refine hardware performance, stimulation protocols, and adaptive algorithms. This iterative, user informed development approach reflects a maturity rarely seen at the seed stage in deep tech.
Further credibility comes from the startup’s regulatory progress. Sychedelic has received approval from India’s Central Drugs Standard Control Organisation (CDSCO), formally classifying the product as a medical device. International patent applications have also been filed, currently holding patent pending status.
The Road Ahead
The freshly secured capital will be channelled into four core priorities: marketing, manufacturing scale up, research expansion, and the execution of a global Kickstarter campaign planned for May 2026. With operations already active across India and the United States, Sychedelic is positioning itself for a disciplined international rollout.
In a landscape where mental health solutions are increasingly in demand yet often superficial in delivery, Sychedelic’s convergence of neuroscience rigour and consumer friendly design presents a genuinely differentiated proposition. The coming months will be pivotal in determining whether the startup can translate early momentum into lasting global impact.
